Ghrelin decreases sensitivity to negative feedback and increases prediction-error related caudate activity in humans, a randomized controlled trial.
Michal PietrzakAdam YngvePaul J HamiltonAnna AsratianEmelie GauffinAndreas LöfbergSarah GustavsonEmil PerssonAndrea J CapusanLorenzo LeggioIrene PeriniGustav TinghögMarkus HeiligRebecca BoehmePublished in: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (2024)
The stomach-derived hormone ghrelin plays not only a role in feeding, starvation, and survival, but it has been suggested to also be involved in the stress response, in neuropsychiatric conditions, and in alcohol and drug use disorders. Mechanisms related to reward processing might mediate ghrelin's broader effects on complex behaviors, as indicated by animal studies and mostly correlative human studies. Here, using a within-subject double-blind placebo-controlled design with intravenous ghrelin infusion in healthy volunteers (n = 30), we tested whether ghrelin alters sensitivity to reward and punishment in a reward learning task. Parameters were derived from a computational model of participants' task behavior. The reversal learning task with monetary rewards was performed during functional brain imaging to investigate ghrelin effects on brain signals related to reward prediction errors. Compared to placebo, ghrelin decreased punishment sensitivity (t = -2.448, p = 0.021), while reward sensitivity was unaltered (t = 0.8, p = 0.43). We furthermore found increased prediction-error related activity in the dorsal striatum during ghrelin administration (region of interest analysis: t-values ≥ 4.21, p-values ≤ 0.044). Our results support a role for ghrelin in reward processing that extends beyond food-related rewards. Reduced sensitivity to negative outcomes and increased processing of prediction errors may be beneficial for food foraging when hungry but could also relate to increased risk taking and impulsivity in the broader context of addictive behaviors.
Keyphrases
- double blind
- placebo controlled
- growth hormone
- prefrontal cortex
- clinical trial
- endothelial cells
- low dose
- metabolic syndrome
- radiation therapy
- spinal cord
- squamous cell carcinoma
- risk assessment
- skeletal muscle
- patient safety
- mass spectrometry
- insulin resistance
- subarachnoid hemorrhage
- phase iii
- obsessive compulsive disorder